The APOC1 antibody targets apolipoprotein C-I (APOC1), a protein encoded by the APOC1 gene, which is a key component of triglyceride-rich lipoproteins such as very low-density lipoproteins (VLDL) and chylomicrons. APOC1 plays a critical role in lipid metabolism by modulating the activity of lipoprotein lipase (LPL) and lecithin-cholesterol acyltransferase (LCAT), thereby influencing plasma lipid levels. Dysregulation of APOC1 has been implicated in various diseases, including cardiovascular disorders, Alzheimer’s disease, and certain cancers, where its overexpression is linked to tumor progression and immune evasion.
APOC1 antibodies are primarily used in research to study the protein’s expression, localization, and function in biological samples. These antibodies enable techniques like Western blotting, immunohistochemistry, and ELISA, helping to elucidate APOC1’s role in metabolic pathways and disease mechanisms. In Alzheimer’s research, APOC1 antibodies have been employed to investigate its association with amyloid-beta aggregation and neuroinflammation. In oncology, they aid in exploring APOC1’s impact on tumor microenvironment modulation and therapeutic resistance.
Recent studies also highlight APOC1 as a potential biomarker for disease prognosis and a target for therapeutic intervention. For instance, neutralizing APOC1 antibodies are being explored in preclinical models to assess their efficacy in disrupting cancer cell survival or restoring lipid homeostasis. The development of high-specificity APOC1 antibodies remains crucial for advancing both diagnostic and therapeutic applications in metabolic and neurodegenerative diseases.